Impax Asset Management Group plc Boosts Stake in Edwards Lifesciences Co. (NYSE:EW)

Impax Asset Management Group plc raised its position in Edwards Lifesciences Co. (NYSE:EW) by 66.2% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 12,964 shares of the medical research company’s stock after purchasing an additional 5,164 shares during the quarter. Impax Asset Management Group plc’s holdings in Edwards Lifesciences were worth $855,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also modified their holdings of the company. Tokio Marine Asset Management Co. Ltd. lifted its position in Edwards Lifesciences by 8.9% during the third quarter. Tokio Marine Asset Management Co. Ltd. now owns 18,140 shares of the medical research company’s stock valued at $1,197,000 after buying an additional 1,480 shares in the last quarter. Metis Global Partners LLC raised its stake in shares of Edwards Lifesciences by 8.8% in the 3rd quarter. Metis Global Partners LLC now owns 41,209 shares of the medical research company’s stock valued at $2,719,000 after acquiring an additional 3,340 shares during the period. KBC Group NV lifted its holdings in shares of Edwards Lifesciences by 13.2% during the 3rd quarter. KBC Group NV now owns 896,162 shares of the medical research company’s stock valued at $59,137,000 after acquiring an additional 104,499 shares in the last quarter. United Super Pty Ltd in its capacity as Trustee for the Construction & Building Unions Superannuation Fund boosted its position in Edwards Lifesciences by 422.3% during the 3rd quarter. United Super Pty Ltd in its capacity as Trustee for the Construction & Building Unions Superannuation Fund now owns 450,233 shares of the medical research company’s stock worth $29,711,000 after purchasing an additional 364,030 shares during the period. Finally, Oppenheimer & Co. Inc. increased its holdings in Edwards Lifesciences by 3.9% in the 3rd quarter. Oppenheimer & Co. Inc. now owns 38,186 shares of the medical research company’s stock valued at $2,520,000 after purchasing an additional 1,441 shares in the last quarter. 79.46% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of research analysts have commented on EW shares. Baird R W cut Edwards Lifesciences from a “strong-buy” rating to a “hold” rating in a research note on Thursday, July 25th. Robert W. Baird reduced their price target on Edwards Lifesciences from $73.00 to $68.00 and set a “neutral” rating on the stock in a research report on Friday, October 25th. UBS Group lowered their price objective on shares of Edwards Lifesciences from $90.00 to $75.00 and set a “neutral” rating for the company in a research report on Tuesday, September 10th. Wolfe Research raised shares of Edwards Lifesciences from an “underperform” rating to a “peer perform” rating in a research report on Monday, July 29th. Finally, Daiwa Capital Markets upgraded shares of Edwards Lifesciences from a “neutral” rating to an “outperform” rating in a research note on Wednesday, July 31st. Seventeen research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $75.67.

Edwards Lifesciences Price Performance

Shares of NYSE:EW opened at $67.76 on Friday. The company has a market cap of $39.96 billion, a PE ratio of 9.78, a P/E/G ratio of 3.74 and a beta of 1.12. Edwards Lifesciences Co. has a fifty-two week low of $58.93 and a fifty-two week high of $96.12. The firm has a 50-day simple moving average of $67.44 and a 200 day simple moving average of $76.18. The company has a quick ratio of 2.89, a current ratio of 3.46 and a debt-to-equity ratio of 0.06.

Edwards Lifesciences (NYSE:EW) last posted its earnings results on Thursday, October 24th. The medical research company reported $0.67 EPS for the quarter, meeting the consensus estimate of $0.67. The company had revenue of $1.35 billion during the quarter, compared to analyst estimates of $1.57 billion. Edwards Lifesciences had a return on equity of 20.76% and a net margin of 70.82%. The business’s revenue was up 8.9% compared to the same quarter last year. During the same period in the prior year, the company earned $0.59 earnings per share. On average, sell-side analysts anticipate that Edwards Lifesciences Co. will post 2.57 EPS for the current year.

Insiders Place Their Bets

In other Edwards Lifesciences news, VP Daveen Chopra sold 1,250 shares of the firm’s stock in a transaction that occurred on Tuesday, August 20th. The shares were sold at an average price of $69.95, for a total value of $87,437.50. Following the sale, the vice president now owns 29,333 shares in the company, valued at approximately $2,051,843.35. This trade represents a 4.09 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Larry L. Wood sold 25,000 shares of the business’s stock in a transaction that occurred on Tuesday, November 5th. The stock was sold at an average price of $65.91, for a total value of $1,647,750.00. Following the transaction, the insider now owns 198,526 shares of the company’s stock, valued at approximately $13,084,848.66. This represents a 11.18 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 41,250 shares of company stock valued at $2,744,438 over the last three months. Company insiders own 1.29% of the company’s stock.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.